Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T21:52:57.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of Amoxicillin-Clavulanate and Resistance in Escherichia coli Over a 4-Year Period

Published online by Cambridge University Press:  02 January 2015

Stephanie Natsch ,
Christian Conrad ,
Cora Hartmeier  and
Beat Schmid
Stephanie Natsch
Affiliation:
Clinical Pharmacy, Hospital of Schaffhausen, Switzerland
Christian Conrad
Affiliation:
Department of Infection Control, Hospital of Schaffhausen, Switzerland
Cora Hartmeier
Affiliation:
Hospital Pharmacy, Hospital of Schaffhausen, Switzerland
Beat Schmid*
Affiliation:
Department of Pharmacy and Laboratory, Hospital of Schaffhausen, Switzerland
*
Hospital Pharmacy, Hospital of Schaffhausen, CH-8208 Schauffhausen, Switzerland
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To reduce the use of amoxicillin-clavulanate after high-resistance rates in Escherichia coli were detected.

Design:

Intervention study; the interventions were introduced successively over a 4-year period while closely monitoring the resistance patterns.

Setting:

A 260-bed acute-care hospital in Switzerland.

Interventions:

Introduction of therapeutic guidelines for specific departments or indications, which proposed alternative antibiotics to amoxicillin-clavulanate. The perioperative prophylactic use of amoxicillin-clavulanate was eliminated completely.

Results:

The absolute amount of amoxicillin-clavulanate consumed decreased by 23%, from 24.8 g per 100 patient days in 1992 to 18.5 g per 100 patient days in 1995. The number of courses, a parameter that takes the prophylactic use into account, decreased by 62% from 2.3 per 100 patient days in 1992 to 0.9 per 100 patient days in 1995. The percentage of sensitive strains increased from 54.9% (n=512) in 1992 and 54.0% (n=506) in 1993 to 72.1% (n=546) in 1994 and 83.1% (n=668) in 1995. No major changes were detected for other antimicrobials, such as cotrimoxazole, tetracycline, or cefuroxime, used in this 4-year period.

Conclusions:

A decrease in the use of amoxicillin-clavulanate was followed by an increase in susceptibility of E coli to it. It was not possible to prove a causative relationship. Only a temporal association was discovered. The reduction of the use of amoxicillin-clavulanate was achieved through the implementation of treatment guidelines, facilitated through a close collaboration among the clinical pharmacists, the infection control practitioner, the microbiology laboratory, and the physicians in charge of the respective departments.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 19 , Issue 9 , September 1998 , pp. 653 - 656
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Buckwold, FJ, Ronald, AR. Antimicrobial misuse—effects and suggestions for control. J Antimicrob Chemother 1979;5:129–136.CrossRefGoogle ScholarPubMed
2. Hollmann, M. Chemotherapeutic-bacteriological interdependences observed by use of a clinical anti-infective drug monitoring system. Eur J Clin Pharmacol 1980;17:101–109.CrossRefGoogle ScholarPubMed
3. Daschner, F, Langmaack, H, Wiedemann, B. Antibiotic resistance in intensive care unit areas. Infect Control 1983;4:382–387.CrossRefGoogle ScholarPubMed
4. McGowan, JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033–1048.CrossRefGoogle ScholarPubMed
5. McGowan, JE Jr. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med 1987;63:253–268.Google ScholarPubMed
6. McGowan, JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478–483.CrossRefGoogle ScholarPubMed
7. Ma, MY, Goldstein, EJ, Friedman, MH, Anderson, MS, Mulligan, ME. Resistance of gram-negative bacilli as related to hospital use of antimicrobial agents. Antimicrob Agents Chemother 1983;24:347–352.CrossRefGoogle ScholarPubMed
8. Ballow, CH, Schentag, JJ. Trends in antibiotic utilization and bacterial resistance. Report of the national nosocomial resistance surveillance group. Diagn Microbiol Infect Dis 1992;15:37S–42S.CrossRefGoogle ScholarPubMed
9. Richard, P, Delangle, MH, Merrien, D, Barille, S, Reynaud, A, Minozzi, C, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994;19:54–59.CrossRefGoogle ScholarPubMed
10. Sanders, CC, Sanders, WE Jr. Beta-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992;15:824–839.CrossRefGoogle ScholarPubMed
11. Henquell, C, Sirot, D, Chanal, C, De Champs, C, Chatron, P, Lafeuille, B, et al. Frequency of inhibitor-resistant TEM p-lactamases in E coli isolates from urinary tract infections in France. J Antimicrob Chemother 1994;34:707–714.CrossRefGoogle Scholar
12. Wu, PJ, Shannon, K, Phillips, I. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of E coli to beta-lactam antibiotics. Antimicrob Agents Chemother 1994;38:494–498.CrossRefGoogle ScholarPubMed
13. Martinez, JL, Cercenado, E, Rodriguez-Creixems, M, Vincente-Perez, MF, Delgado-Iribarren, A, Baquero, F. Resistance to beta-lactam-clavulanate. Lancet 1987;2:1473.CrossRefGoogle ScholarPubMed
14. Reguera, JA, Baquero, F, Perez-Diaz, JC, Martinez, JL: Factors determining resistance to ß-lactam combined with ß-lactamase inhibitors in E coli . J Antimicrob Chemother 1991;27:569–575.CrossRefGoogle Scholar
15. Sirot, D, Chanal, C, Henquell, C, Labia, R, Sirot, J, Cluzel, R. Clinical isolates of E coli producing multiple TEM mutants resistant to beta-lactamase inhibitors. J Antimicrob Chemother 1994;33:1117–1126.CrossRefGoogle ScholarPubMed
16. Zhou, XY, Bordon, F, Sirot, D, Kitzis, MD, Gutmann, L. Emergence of clinical isolates of E coli producing TEM-1 derivatives or an oxa-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother 1994;38:1085–1089.CrossRefGoogle ScholarPubMed
17. Blazquez, J, Baquero, MR, Canton, R, Alos, I, Baquero, F. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of E coli . Antimicrob Agents Chemother 1993;37:2059–2063.CrossRefGoogle Scholar
18. Wust, J, Auckenthaler, R, Breer, C, Frei, R, Heinzer, I, Kamm, W. Antibiotika-Empfindlichkeit von gramnegativen Bakterien auf Intensivpflegestationen in der Schweiz. Schweiz Med Wochenschr 1994;124:1695–1700.Google Scholar
19. Kastanakis, S, Tzimis, L, Papadomanolaki, E, Alevraki, G, Tsouri, A, Koutsouba, D, et al. Resistance patterns of E coli in a general hospital on the island of Crete. Medical Microbiology Letters 1996;5:S79.Google Scholar
20. Kouppari, G, Zaphiropoulou, A, Tsirepa, M, Xenos, N, Deliyianni, V, Dellagrammaticas, H. Resistance of E coli isolated from neonates. Medical Microbiology Letters 1996;5:S83.Google Scholar
21. Mueller, ML, Conrad, C, Schmid, B. Epidemiologische Datenanalyse im Krankenhaus: Einsatz eines online-computer systems zur automatisierten Erreger- und Resistenzstatistik. Krh.-Hyg. + Inf.verh. 1997;19:43–47.Google Scholar
22. Barry, AL, Thornsberry, C: Susceptibility tests: diffusion test procedures. In: Balows, A, Hausler, WJ, Herrmann, KL, Isenberg, HD, Shadomy, HJ, eds. Manual of Clinical Microbiology. Washington DC, American Society for Microbiology; 1991:1117–1125.Google Scholar